| Name | Title | Contact Details |
|---|
Primus Pharmaceuticals, Inc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Primus Pharmaceuticals, Inc is based in Scottsdale, AZ. You can find more information on Primus Pharmaceuticals, Inc at www.primusrx.com
Built around a portfolio of recognized brands, Golden Leaf Holdings Incorporate is one of the largest cannabis oil and solution providers in North America. The Company leverages a strong management team with cannabis and food industry experience to complement its expertise in the extracting, refining and selling of cannabis oil, edibles and flower products. The Company has developed a strong consumer brand portfolio (“Golden Brands”) that includes the Golden, Proper, Chalice Farms, Liberty Reach and Jackpot Seaweed brands. In addition to leading branded products, Golden Leaf also maintains a foothold in the Oregon retail dispensary market with its award-winning chain of Chalice Farms retail stores.
CAnCare of Houston is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Corazon Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.